QR-koda

Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system

IntroductionIn 2021 ofatumumab, a recombinant human anti-CD20 monoclonal antibody (mAb) already authorized for the treatment of chronic lymphocytic leukemia, received the marketing approval for the treatment of relapsing forms of multiple sclerosis (MS). Differently from ocrelizumab, that is adminis...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Cristina Scavone, Antonietta Anatriello, Isabella Baccari, Andrea Cantone, Daniele Di Giulio Cesare, Francesca Futura Bernardi, Ornella Moreggia, Valerio Liguori, Vincenzo Andreone, Giorgia Teresa Maniscalco, Annalisa Capuano
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Frontiers Media S.A. 2024-06-01
Ráidu:Frontiers in Neurology
Fáttát:
Eudravigilance
infusion reactions
injective reactions
multiple sclerosis
ocrelizumab
ofatumumab
Liŋkkat:https://www.frontiersin.org/articles/10.3389/fneur.2024.1383910/full
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid